1,066 results on '"Scolyer, Richard A."'
Search Results
2. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response
3. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
4. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
5. Interobserver agreement in the histopathological classification of desmoplastic melanomas.
6. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
7. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions
8. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors
9. Uncovering the complex relationship between balding, testosterone and skin cancers in men
10. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
11. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
12. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
13. Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial
14. L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases
15. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
16. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
17. Prognostic Gene Expression Profiling in Cutaneous Melanoma
18. Hypoxia Controls the Glycome Signature and Galectin-8–Ligand Axis to Promote Protumorigenic Properties of Metastatic Melanoma
19. Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets
20. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
21. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
22. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
23. LNK suppresses interferon signaling in melanoma.
24. Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas
25. Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma
26. Anatomic position determines oncogenic specificity in melanoma
27. Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine
28. Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes
29. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
30. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
31. Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework
32. Histological regression in melanoma: impact on sentinel lymph node status and survival
33. High response rate to PD-1 blockade in desmoplastic melanomas.
34. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.
35. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
36. Health Economic Consequences Associated With COVID-19–Related Delay in Melanoma Diagnosis in Europe
37. Counting mitoses: SI(ze) matters!
38. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
39. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status
40. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
41. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
42. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
43. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
44. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
45. Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management
46. The prognostic significance of microsatellites in cutaneous melanoma
47. Melanoma pathology reporting and staging
48. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
49. Prediction of Sentinel Node Positivity Risk in Melanoma Patients: When Appropriate Statistical Methodology was Employed an i31-GEP Test Did Not Outperform a Tool that Uses Clinicopathologic Features Only
50. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.